Literature DB >> 11886718

Anti-cardiolipin, anti-cardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population.

Javier Cabiedes1, Jorge Trejo-Hernández, Arturo Loredo-Abdalá, Luis Castilla-Serna, A Tamara López-Mendoza, Hugo A Cordero-Esperón, M Teresa Huerta, Antonio R Cabral, Donato Alarcón-Segovia.   

Abstract

BACKGROUND: Pathogenic antiphospholipid antibodies studies are usually conducted on populations of adults. Studies involving normal children are scant.
METHODS: Antibody reactivity against CL alone (true aCL), CL-complexed to bovine beta(2)GP-I (aCL-bovine beta(2)GP-I), or human (aCL-human beta(2)GP-I) beta(2)GP-I, or to phospholipid-free human beta(2)GP-I (anti-human beta(2)GP-I) was determined by ELISA in serum samples from 360 Mexican children ranging from 1 month through 8 years of age.
RESULTS: Statistical analysis of variance and rankings of Kruskal-Wallis demonstrated no significant difference in all tested antibody activities between ages and genders of the study population. Values are presented as a percentile distribution included between 5 and 99, corresponding to the percentages of the studied population. Normal arbitrary units (AU) for IgG, IgA, and IgM true aCL that correspond to the 95 and 99 percentiles are as follows: 2.15 and 3.5; 2.35 and 5.0, and 3.15 and 4.5, respectively. IgG, IgA, and IgM aCL-bovine beta(2)GP-I activities are 2.6 and 5.0, 3.0 and 5.0, and 2.7 and 6.0 AU, respectively, while IgG activities of aCL-bovine and human beta(2)GP-I are 1.45 and 1.80, respectively. Normal values for IgG anti-human beta(2)GP-I are 1.85 AU.
CONCLUSIONS: While elevated serum levels of antibodies to CL and/or beta(2)GP-I have been associated with thrombotic and hematologic manifestations, the majority of reports deal with adult populations. We report the cut-off values (in AU, international PL units, and international units for beta(2)GP-I) of the specific serologic response of true aCL, aCL-bovine beta(2)GP-I, aCL-human beta(2)GP-I, and anti-human beta(2)GP-I in healthy Mexican children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886718     DOI: 10.1016/s0188-4409(01)00359-9

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  4 in total

1.  Anticardiolipin antibodies in dogs.

Authors:  R Papini; O Pellegrini; C Rossini; G Guidi
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 2.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

Review 4.  Epidemiology of Antiphospholipid Syndrome in the General Population.

Authors:  Jesse Y Dabit; Maria O Valenzuela-Almada; Sebastian Vallejo-Ramos; Alí Duarte-García
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.